What is it about?
Non-small cell lung cancer (NSCLC) is being treated with a new type of drug class called biologics. These drugs target a specific pathway and inhibit their activity and treat cancer. A new drug, nivolumab, inhibits the PD-1/PD-L1 pathway with much promise in treatment of NSCLC.
Featured Image
Why is it important?
Nivolumab is increasingly being used to treat non-small cell lung cancer in patients with stage 3/4 cancer. It is important for clinicians to understand its clinical significance in the treatment of these patients. Similar biologics from other drug companies are being developed for similar indications and knowing the mechanism and its context in treatment will be increasingly important.
Perspectives
The advent of immune checkpoint inhibitors, such as nivolumab, adds a new repertoire of agents in the treatment of non-small cell lung cancer (NSCLC). Further research will clarify its role in combination with surgery or chemotherapy. Immune checkpoint inhibitors are currently and will continue to play a key role in the treatment of NSCLC.
Dr Saeed K. Alzghari
Gulfstream Diagnostics
Read the Original
This page is a summary of: Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context, Therapeutics and Clinical Risk Management, February 2017, Dove Medical Press,
DOI: 10.2147/tcrm.s104343.
You can read the full text:
Contributors
The following have contributed to this page
